Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ATM mutant |
| Therapy | Talazoparib |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ATM mutant | Advanced Solid Tumor | predicted - sensitive | Talazoparib | Phase II | Actionable | In a Phase II trial (TAPUR), Talzenna (talazoparib) treatment resulted in a disease control rate of 41% and an objective response rate of 7% in advanced solid tumor patients harboring ATM mutation (n=28) or deletion (n=1) with 1 partial response in a thyroid cancer patient and 1 partial response in a lung cancer patient ongoing at 73 weeks (Cancer Res (2025) 85 (8_Supplement_2): CT228). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Abstract CT228: Talazoparib (Tala) in patients (pts) with solid tumors with ATM alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study | Full reference... |